Ireland· IE-PA-EU/1/09/544/1-2
Cimzia 200 mg solution for injection in pre-filled syringe
A certolizumab pegol product containing certolizumab pegol, registered in Ireland by UCB Pharma S.A.. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Certolizumab pegol is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB05 (certolizumab pegol), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Certolizumab pegol · ATC L04AB05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of certolizumab pegol costs, country by country.
Normalised to the WHO defined daily dose (14 mg), the median price runs from $0.17 in Finland to $41.63 in Switzerland — a ×241 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Certolizumab pegol · price per daily dose (14 mg)
USD · FX 28 Sept 2026
- CH Switzerland$41.63
- FI Finland$0.17
The record
At a glance
HPRA (Ireland)- Active substance
- Certolizumab pegol
- Manufacturer
- UCB Pharma S.A.
- Country
- Ireland (IE)
- ATC code
- L04AB05
- ATC class
- Certolizumab pegol
- Defined daily dose
- 14 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/09/544/1-2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
430 interactions on record for certolizumab pegol.
Graded by severity as the source publishes them — 286 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Certolizumab pegol · interactions on record
430 records
- 286 severe
- 137 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Certolizumab pegol in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceCIMZIA 200 mg solution injectable en seringue préremplieUCB PHARMA BELGIQUE
- NetherlandsCimzia 200 mgUCB Pharma S.A.
- CzechiaCIMZIAUCB Pharma SA, Brusel
- FinlandCimziaParanova Oy
- SpainCIMZIA 200 MG SOLUCION INYECTABLE EN CARTUCHO PARA DISPENSADOR DE DOSISUcb Pharma
- BelgiumCimzia 200 mgUCB Pharma
- United KingdomCimzia 200mg/1ml solution for injection in a dose-dispenser cartridgeUCB Pharma Ltd
- IcelandCimziaUCB Pharma S.A.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cimzia
- Liechtenstein · Cimzia
- Norway · Cimzia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/97704668-2a55-4a60-8e98-2f6f151e703e GET /v1/drugs/97704668-2a55-4a60-8e98-2f6f151e703e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"L04AB",
"L04AB05"
],
"strength": null,
"pa_number": "EU/1/09/544/1-2",
"substances": [
"Certolizumab pegol"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about certolizumab pegol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.